2022 World Conference on Lung Cancer (ePosters)-EP14.01-025. Anlotinib Plus Standard Chemotherapy as First-line Treatment in Extensive-Stage Small Cell Lung Cancer Patients

Pdf Summary

The study investigated the efficacy and safety of anlotinib, a drug that has shown promise in treating small cell lung cancer (SCLC), in combination with standard chemotherapy as a first-line treatment for patients with extensive-stage SCLC (ES-SCLC). ES-SCLC is known to have a poor prognosis.<br /><br />The study included cytologically or histologically confirmed untreated ES-SCLC patients with a performance status of 0 or 1. Patients with asymptomatic central nervous system metastases were also included. The patients received up to six cycles of chemotherapy consisting of etoposide with either carboplatin or cisplatin. Anlotinib was orally taken once daily for two weeks on and one week off, in addition to the chemotherapy. Treatment was continued until disease progression, intolerable side effects, or withdrawal of consent.<br /><br />The primary endpoints of the study were safety and objective response rate (ORR) assessed by the investigators. Over the course of the study, 86 patients received at least one dose of treatment and were included in the analysis. The median follow-up was 27.9 months.<br /><br />The baseline characteristics of the patients showed that the majority were male with a smoking history. The most common distant metastasis sites were the bone, liver, and brain. The starting dosage of anlotinib was 8mg, 10mg, or 12mg. The median duration of anlotinib treatment was 9.6 months, while the median duration of chemotherapy was 4.0 months. A total of 62 patients received later lines of therapy.<br /><br />The study results showed promising efficacy and safety profiles for the combination of anlotinib and chemotherapy in ES-SCLC patients. The overall survival and progression-free survival rates were analyzed using Kaplan-Meier estimates. Adverse events were reported in 91.9% of patients, with grade 3 or higher adverse events occurring in 58.1% of patients. The most common treatment-related adverse events were leukopenia, granulocytopenia, oral mucositis, and fatigue.<br /><br />In conclusion, the study suggests that the addition of anlotinib to first-line treatment with platinum and etoposide may offer a potential and novel treatment option for patients with ES-SCLC. However, further validation through randomized trials is necessary.

Asset Subtitle

Wei Zhang

Meta Tag

Speaker Wei Zhang

Topic Small Cell Lung Cancer and Neuro-endocrine Tumours - Informing ES-SCLC

Keywords

anlotinib

small cell lung cancer

SCLC

extensive-stage SCLC

chemotherapy

first-line treatment

efficacy

safety

objective response rate

adverse events